The efficacy and safety of intravenous hydralazine for the treatment of hypertension in the hospitalized child
- 556 Downloads
Intravenous (IV) hydralazine is frequently used for the treatment of elevated blood pressure (BP) in hospitalized children. Its safety and efficacy have not been examined.
This is a retrospective chart review of IV hydralazine use in hospitalized children (birth to 17 years) over a 3-year period. Demographic data and data on adverse effects (AE), BP, and heart rate (HR) prior to and after each first dose were collected.
The patient cohort comprised 110 children admitted to the hospital during the study period, of whom 77 received the recommended dose. Mean age of the children was 8.5 ± 5.4 years; 33 % were male, and 32.5 % were white. Pre-dose systolic and diastolic BP indexes were 1.3 and 1.2, respectively. The median reduction in systolic and diastolic BP was 8.5 and 11.5 %, respectively. Sixteen (21 %) children achieved a 25 % reduction in systolic or diastolic BP, and BP increased in 30 % of patients; 10 % of children had a BP of <95th percentile for age, sex, and height after one dose. Seven (9 %) children had a documented AE. HR increased by a median of 3.5 %. In the multivariable models examining percentage change in systolic and diastolic BP, male gender was significantly associated with a change in systolic BP.
In hospitalized children, IV hydralazine was well tolerated, BP response was variable, and 21 % of the patients achieved a ≥25 % reduction of systolic or diastolic BP. Further studies are needed to compare the safety and efficacy of IV hydralazine to other short-acting antihypertensive agents.
KeywordsElevated blood pressure Hydralazine Intravenous Hospitalized Pediatric Medication safety Drug therapy
- 1.National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576Google Scholar
- 2.Taketomo CK, Hodding JH, Kraus DM (2013) Pediatric & neonatal dosage handbook, vol 20th. American Pharmacists Association, LexicompGoogle Scholar
- 7.Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL (2002) 2000 CDC growth charts for the United States: methods and development. Vital and Health Statistics Series 11, Number 246. U.S. Center for Disease Control and Prevention, AtlantaGoogle Scholar
- 8.(1952) NEW approved drugs: hexamethonium bromide; hydralazine hydrochloride. Med Bull (Ann Arbor) 18:185–187Google Scholar
- 11.Kandler MR, Mah GT, Tejani AM, Stabler SN, Salzwedel DM (2011) Hydralazine for essential hypertension. Cochrane Database Syst Rev 2011;(11):CD004934Google Scholar
- 13.Devlin JW, Dasta JF, Kleinschmidt K, Roberts RJ, Lapointe M, Varon J, Anderson FA, Wyman A, Granger CB (2010) Patterns of antihypertensive treatment in patients with acute severe hypertension from a nonneurologic cause: Studying the Treatment of Acute Hypertension (STAT) registry. Pharmacotherapy 30:1087–1096PubMedCrossRefGoogle Scholar